Unity Biotechnology, Inc.

NasdaqGS UBX

Unity Biotechnology, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

Unity Biotechnology, Inc. Net Cash Used Provided By Financing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Unity Biotechnology, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 84.23 M, a 1,126.56% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: UBX

Unity Biotechnology, Inc.

CEO	Dr. Anirvan Ghosh Ph.D.
IPO Date	May 3, 2018
Location	United States
Headquarters	285 East Grand Avenue
Employees	19
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals

Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Key trends

Past 5 years